Clinical Trial

Trial Protocol ID TPX-0005-07 *RIT*

Trial Description

A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Disease Types

Sponsor

  • Turning Point Therapeutics, Inc.

ClinicalTrials.gov NCT ID

  • NCT04094610